1.78
price up icon1.14%   0.02
after-market アフターアワーズ: 1.96 0.18 +10.11%
loading
前日終値:
$1.76
開ける:
$1.9
24時間の取引高:
185.70K
Relative Volume:
4.87
時価総額:
$180.67M
収益:
$5.15M
当期純損益:
$-65.35M
株価収益率:
-0.8945
EPS:
-1.99
ネットキャッシュフロー:
$-20.85M
1週間 パフォーマンス:
-2.73%
1か月 パフォーマンス:
-6.02%
6か月 パフォーマンス:
-40.47%
1年 パフォーマンス:
-37.76%
1日の値動き範囲:
Value
$1.78
$1.90
1週間の範囲:
Value
$1.75
$1.90
52週間の値動き範囲:
Value
$1.75
$3.7735

Cellectis Adr Stock (CLLS) Company Profile

Name
名前
Cellectis Adr
Name
セクター
Healthcare (1182)
Name
電話
-
Name
住所
-
Name
職員
216
Name
Twitter
@cellectis
Name
次回の収益日
2024-11-04
Name
最新のSEC提出書
Name
CLLS's Discussions on Twitter

Cellectis Adr Stock (CLLS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-03-17 開始されました Bryan Garnier Buy
2022-05-18 アップグレード Robert W. Baird Neutral → Outperform
2022-01-06 ダウングレード Wells Fargo Overweight → Equal Weight
2021-11-30 開始されました JMP Securities Mkt Outperform
2021-11-08 ダウングレード William Blair Outperform → Mkt Perform
2021-10-08 ダウングレード Robert W. Baird Outperform → Neutral
2021-04-28 ダウングレード Guggenheim Buy → Neutral
2021-03-16 アップグレード Robert W. Baird Neutral → Outperform
2020-08-19 アップグレード Citigroup Neutral → Buy
2020-05-12 開始されました Robert W. Baird Outperform
2020-03-06 ダウングレード Goldman Neutral → Sell
2019-10-30 再開されました Guggenheim Buy
2019-08-09 開始されました BTIG Research Buy
2019-05-24 再開されました Citigroup Neutral
2019-03-14 開始されました William Blair Outperform
2018-12-19 開始されました Goldman Neutral
2018-07-16 開始されました Barclays Overweight
2018-03-16 開始されました Guggenheim Neutral
2017-09-05 ダウングレード SunTrust Buy → Hold
2017-09-05 繰り返されました Wells Fargo Outperform
2017-03-02 開始されました Instinet Buy
2017-02-28 開始されました Wells Fargo Outperform
2016-04-05 開始されました Ladenburg Thalmann Buy
2016-03-02 開始されました Sun Trust Rbsn Humphrey Buy
2015-07-20 開始されました BofA/Merrill Buy
2015-04-20 開始されました Jefferies Buy
2015-04-20 開始されました Piper Jaffray Overweight
すべてを表示

Cellectis Adr (CLLS) 最新ニュース

pulisher
02:16 AM

Baird maintains $10 target on Cellectis amid strong AZN partnership - Investing.com

02:16 AM
pulisher
Nov 04, 2024

Cellectis earnings missed by $0.03, revenue topped estimates - Investing.com

Nov 04, 2024
pulisher
Oct 30, 2024

Cellectis stock touches 52-week low at $1.77 amid market shifts By Investing.com - Investing.com South Africa

Oct 30, 2024
pulisher
Oct 30, 2024

500: Something went wrong - Investing.com

Oct 30, 2024
pulisher
Oct 25, 2024

European Equities Traded in the US as American Depositary Receipts Nudge Lower in Tuesday Trading - MSN

Oct 25, 2024
pulisher
Oct 12, 2024

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remains Down for Week - MSN

Oct 12, 2024
pulisher
Oct 09, 2024

European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher - MSN

Oct 09, 2024
pulisher
Oct 09, 2024

European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading - MSN

Oct 09, 2024
pulisher
Oct 03, 2024

European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN

Oct 03, 2024
pulisher
Oct 02, 2024

Monthly information on share capital and company voting rights - GlobeNewswire Inc.

Oct 02, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: Cellectis stock rides wave of innovation amid biotech challenges - Investing.com

Sep 27, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: Cellectis stock rides wave of innovation amid biotech challenges By Investing.com - Investing.com South Africa

Sep 27, 2024
pulisher
Sep 13, 2024

European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - MSN

Sep 13, 2024
pulisher
Sep 06, 2024

European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - MSN

Sep 06, 2024
pulisher
Aug 30, 2024

European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN

Aug 30, 2024
pulisher
Aug 22, 2024

European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN

Aug 22, 2024
pulisher
Aug 21, 2024

European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading - MSN

Aug 21, 2024
pulisher
Jul 26, 2024

A year in review: Cellectis ADR (CLLS)’s performance in the last year - US Post News

Jul 26, 2024
pulisher
Jul 05, 2024

Monthly information on share capital and company voting rights - GlobeNewswire Inc.

Jul 05, 2024
pulisher
Jun 19, 2024

Market Insights: Cellectis ADR (CLLS)'s Notable Drop of -5.84, Closing at 2.02 – DWinneX - The Dwinnex

Jun 19, 2024
pulisher
Jun 18, 2024

Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors - The Globe and Mail

Jun 18, 2024
pulisher
Jun 18, 2024

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results - The Globe and Mail

Jun 18, 2024
pulisher
Jun 14, 2024

European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading - MSN

Jun 14, 2024
pulisher
Jun 12, 2024

Cellectis shares target cut by Oppenheimer on revised model post-Q1 results - Investing.com India

Jun 12, 2024
pulisher
Jun 12, 2024

Cellectis shares target cut by Oppenheimer on revised model post-Q1 results By Investing.com - Investing.com UK

Jun 12, 2024
pulisher
May 31, 2024

European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower - MSN

May 31, 2024
pulisher
May 31, 2024

Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca By Investing.com - Investing.com India

May 31, 2024
pulisher
May 30, 2024

Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca - Investing.com India

May 30, 2024
pulisher
May 18, 2024

European Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading - MSN

May 18, 2024
pulisher
May 17, 2024

European Equities Traded in the US as American Depositary Receipts Fall Again in Tuesday Trading - MSN

May 17, 2024
pulisher
Dec 16, 2023

CellectisADR (CLLS) Price Target Increased by 20.85% to 11.75 - MSN

Dec 16, 2023
pulisher
Feb 21, 2023

There's a Lot of Upside For Emerging Gene-Editing Companies - The Globe and Mail

Feb 21, 2023
pulisher
Jun 30, 2022

Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing - Nature.com

Jun 30, 2022
pulisher
Apr 28, 2022

Cytovia Therapeutics To Go Public Via $600 Million SPAC Merger - Equities News

Apr 28, 2022
pulisher
Apr 09, 2021

Cellectis Completes Sale of $47 million through its ATM program - The Globe and Mail

Apr 09, 2021
pulisher
Mar 29, 2021

Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq - The Globe and Mail

Mar 29, 2021
pulisher
Feb 21, 2021

Current Cathie Wood Portfolio 2021: Ark Invest Holdings - New Trader U

Feb 21, 2021
pulisher
Dec 28, 2020

Current Cathie Wood Portfolio 2020: Ark Invest Holdings - New Trader U

Dec 28, 2020
pulisher
Nov 21, 2019

The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon - Yahoo Finance

Nov 21, 2019
pulisher
Jan 17, 2018

30 Stocks Moving In Wednesday's Pre-Market SessionAdtran Holdings (NASDAQ:ADTN), Adient (NYSE:ADNT) - Benzinga

Jan 17, 2018
pulisher
Oct 18, 2017

7 Gene Editing Companies Investors Should Watch - Nanalyze

Oct 18, 2017
pulisher
Sep 05, 2017

25 Stocks Moving In Tuesday's Pre-Market SessionBioCryst Pharma (NASDAQ:BCRX) - Benzinga

Sep 05, 2017
pulisher
Aug 28, 2017

25 Stocks Moving In Monday's Pre-Market SessionAltisource Portfolio (NASDAQ:ASPS) - Benzinga

Aug 28, 2017
pulisher
Feb 08, 2017

Top 10 Luxury Car Brands In The World - Insider Monkey

Feb 08, 2017
pulisher
Aug 11, 2016

Cellectis (CLLS) Stock Price, News & AnalysisNASDAQ - MarketBeat

Aug 11, 2016
pulisher
Dec 01, 2015

15 Biotechs Making Announcements At The 2015 Piper Jaffray Healthcare ConferenceAbeona Therapeutics (N - Benzinga

Dec 01, 2015
pulisher
Oct 29, 2015

Morning Market GainersCellectis (NASDAQ:CLLS) - Benzinga

Oct 29, 2015
pulisher
Oct 27, 2015

New Strong Buy Stocks for October 27th - Nasdaq

Oct 27, 2015
pulisher
Jul 20, 2015

BofA Starts Cellectis At Buy, Sees Plant Sciences As 'Hidden Gem'Cellectis (NASDAQ:CLLS) - Benzinga

Jul 20, 2015

Cellectis Adr (CLLS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
大文字化:     |  ボリューム (24 時間):